2. Sources and Formation of AGEs
AGEs originate from either endogenous or exogenous sources
[26][16]. Approximately 30% of AGEs are absorbed into the systemic circulation via gastrointestinal absorption and the influence of the systemic burden. A high burden of AGEs is related to oxidative stress, inflammation, impaired innate defense, and insulin resistance
[27][17]. Heterogeneous AGEs rely on the specific structure of protein-bound AGEs and are divided into protein-bound, peptide-bound, or free forms of AGEs. Unabsorbed AGEs in the colon are crucial factors for compromised glycemic control
[28][18].
In contrast, AGEs are generated predominantly through endogenous processes via the nonenzymatic reaction of glucose-derived carbonyls with amino groups of lysine and arginine protein residues by forming unstable Schiff bases and stable Amadori products or fructosyl lysine, such as glycated hemoglobin, which is used in the diagnosis of DM, or follow-up modalities, and fructosamine
[29][19]. This process, involving the formation of Schiff bases and Amadori products, is known as the Maillard reaction
[25][20]. Both of these compounds are reversible and react irreversibly with protein and peptide to form crosslinks.
AGEs have been categorized into two groups depending on their structure: the first group includes N-carboxymethyllysine (CML), pentosidine, crossline, pyrraline, and hydroimidazolone
[35][21]; the second group includes AGE-1 (glucose-derived AGEs), AGE-2 (glyceraldehyde-derived AGEs), AGE-3 (glycolaldehyde-derived AGEs), AGE-4 (MGO/methylglyoxal-derived AGEs), AGE-5 (glyoxal-derived AGEs), AGE-6 (3-deoxyglucosone-derived AGEs), and acetaldehyde-derived AGEs (AA-AGEs)
[36][22].
Thus, the formation and biochemistry of AGEs have been well-established elsewhere. AGEs formation extends the damage to macromolecules in tissue with structural and functional alterations
[37][23]. Nevertheless, the mechanism of metabolic memory-related diabetic complications needs to be further investigated.
3. AGEs Interactions with Receptors
Exogenous AGEs and spontaneously produced endogenous AGEs interact through various signaling pathways and several AGEs receptors. AGEs bind into the extracellular transmembrane receptor and initiate signaling cascades. Among several receptors, the receptor for advanced glycation end products (RAGE) is a central transduction receptor of AGEs. RAGE, which is encoded on chromosome 6 near major histocompatibility complex III, is incorporated into a member of the immunoglobulin superfamily and recognized by its three-dimensional form rather than by specific amino acid sequences
[38][24]. RAGE is expressed everywhere at a low level of RAGE ligand: endothelial cells, macrophages, monocytes, neurons, vascular smooth muscle cells, or chondrocytes
[39,40][25][26]. However, RAGE is activated with an increase in the level of RAGE ligands in inflammation and its related responses. Thus, RAGE regulates inflammation via NF-ĸB, TNF-α, oxidative stress, and dysfunction of endothelial cells in type 2 DM
[41][27]. In addition to the membrane-bound form of RAGE, there are two types of circulating soluble RAGEs (sRAGE) without transmembrane and cytoplasmic domains
[42][28]. sRAGE is produced by cleavage of the cell surface receptor (cRAGE), which is generated by matrix metalloproteinases (MMPs) or by alternative splicing of endogenous secretory RAGE (esRAGE)
[43][29]. Ligand binding enhances RAGE shedding, and serum sRAGE is considered representative of tissue RAGE expression
[44][30]. Isoforms such as sRAGE and esRAGE bind RAGE ligands and block the interaction between membrane RAGE and cellular responses
[45][31]. However, the exact function of sRAGE remains uncertain.
There is evidence of an increase in low-grade inflammation in type 2 DM. High levels of AGEs in type 2 DM patients are correlated with increased RAGE mRNA expression, protein carbonyl levels, and lipid peroxidation
[46][32]. Moreover, the activation of signaling cascades, including NF-ĸB, and oxidative stress from AGE/RAGE interactions stimulate inflammation and tissue injury through the expression of vascular cell adhesion molecules, monocyte chemoattractant protein-1, endothelin-1, and plasminogen activator inhibitor-1 (PAI-1), and these factors are involved in vascular and tissue damage
[47,48][33][34]. Therefore, AGEs with RAGE act as surrogate markers of inflammation, and their levels increase in chronic metabolic-inflammatory disorders
[40][26].
In addition to RAGEs, the other classes of receptors are scavenger receptors, such as Stab1and Stab2, and AGE receptors (AGERs), such as AGE-R1~AGER
[49,50][35][36]. These receptors can recognize and bind AGE ligands without the transduction of cellular signaling after engagement by AGEs. They have a role in the detoxification of AGEs and of AGE-specific ligand binding with degradation
[51][37]. The expression of AGE-R1 was decreased, and AGE levels were elevated in DM patients
[52,53][38][39]. AGE-R3 is hyperactive with hyperglycemia and high levels of AGEs
[54][40].
4. Pathogenesis of Diabetic Vascular Complications and AGEs in Type 2 DM
Chronic complications of type 2 DM are caused by structural or functional modification of the vasculature. Structural modification results from extracellular or intracellular proteins or polypeptides that are vulnerable to modification by AGEs
[55][41]. AGEs are found in the serum, the vasculature, the retina, and various renal compartments, such as the glomerulus and basement membrane
[50][36]. Therefore, AGEs are involved in damage to multiple tissues or organs in type 2 DM after long-term exposure to hyperglycemia. Chronic hyperglycemia in uncontrolled type 2 DM accelerates the accumulation of AGE precursors, such as MGO, and activates the protein kinase C pathway, followed by increases in oxidative stress and inflammatory cytokine levels. Along with AGE accumulation, the AGE–RAGE axis is correlated with diabetic complications in patients with type 2 DM. Long-term DM complications are mainly categorized as microvascular complications, such as diabetic retinopathy (DR), nephropathy (DN), and peripheral neuropathy (DPN), and macrovascular complications, including cardiovascular disease, cerebrovascular disease, and PVD.
4.1. Microvascular Complications and AGEs
Microvascular complications are defined as the presence of retinopathy, nephropathy with albuminuria, and neuropathy
[56,57][42][43]. Different organs are linked to these complications. DN is the leading cause of renal failure and is defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m
2, and/or microalbuminuria > 3 mg/g, or an albumin-to-creatinine ratio (ACR) ≥ 3 mg/mmol in patients with DM
[58,59][44][45]. The mechanism of DN is related to glomerular hypertrophy, renal oxidative stress, and fibrosis. Glomerular changes such as the thickening of tubular basement membranes, mesangial hypertrophy, and loss of podocytes are provoked by AGEs. RAGEs are also found in tubular epithelial cells and glomerular cells, including podocytes and mesangial cells. The activation of RAGE from AGEs enhances RAGE expression. Therefore, RAGE expression is prevalent where AGEs accumulate. Tubular cells are exposed to a large amount of AGEs and increase the activation of intracellular signaling pathways via their highly expressed RAGE
[60][46]. This process is crucial for the development of interstitial fibrosis and glomerular dysfunction during the early phase in type 2 DM
[60][46]. Therefore, recent studies have focused on the therapeutic effects of RAGE blockade in DN
[61,62,63,64][47][48][49][50].
The AGE–RAGE pathway is activated via various signaling cascades, such as phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/IκB kinase (IKK), and NF-κB activation
[51][37]. NF-κB binds to the RAGE promoter and enhances RAGE expression. Increased levels of NF-κB in the kidney activate glomerular and tubular cell damage and induce renal injury. NF-κB also affects adhesion molecules and proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and monocyte chemoattractant protein (MCP)-1. These factors are involved in the development of DN. IL-6 is involved in pathologic changes in mesangial cells, and MCP-1 plays a role in mesangial cell proliferation. The AGE–RAGE interaction promotes reactive oxygen species (ROS), and ROS enhances the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway
[53,65,66][39][51][52]. JAK-STAT signaling has a crucial role in mesangial cells, podocytes, and epithelial cells and induces glomerular hypertrophy by inducing growth factors, including tumor growth factor (TGF)-β, platelet-derived growth factor (PDGF)-β, and IGF-binding protein-related protein-2
[67][53]. TGF-β regulates inflammation by upregulating MCP-1 and NF-κB
[68][54].
AGEs themselves are involved in the progression of DN. AGEs form cross-links with matrix proteins such as collagen, leading to structural changes and inducing DM glomerulosclerosis with the accumulation of plasma proteins, lipid proteins, and immunoglobulin
[69][55]. In addition to structural changes, the nonenzymatic glycation of type IV collagen provokes vascular permeability to albumin and the interaction with negatively charged proteoglycans
[70][56]. In renal systems, the renin–angiotensin system (RAS), which comprises renin, angiotensinogen, angiotensin I, angiotensin-converting enzyme (ACE), angiotensin II, and their receptors, is a key factor in blood pressure and fluid balance. AGEs are involved in activated angiotensin II and trigger mesangial hypertrophy
[70][56]. Angiotensin II also induces ROS production
[71,72][57][58].
DR is characterized by abnormal vascular proliferation, which accompanies hemorrhage and ischemia in the retina. AGEs and CML are located in retinal vessels, and the levels are positively correlated with DR according to previous studies
[54,73][40][59]. The AGE–RAGE pathway induces the apoptosis of pericytes and increases oxidative stress via NF-κB production. Increased levels of NF-κB upregulate vascular endothelial growth factor (VEGF) and allow endothelial permeability
[74][60]. ROS generation, as in DN, can aggravate angiogenesis and vascular permeability. These pathologic changes cause damage to the subretinal membrane and microvasculature
[75][61].
The role of AGEs in DPN is well established. DPN is stratified into the endothelium of the vasa nervorum, the sensory neuron (dorsal root), and Schwann cells
[76][62]. As with DR, vascular dysfunction via the accumulation of AGEs in the endothelium of the vasa nervorum causes damage to the vascular structure and ischemia or occlusion. AGEs reduce the conduction of sensory and motor nerves and nerve blood flow
[77][63]. The glycation of collagen and laminin induces alterations in the basement membrane and increases the permeability of vessels. Increased RAGE levels in dorsal root neurons activate the NF-kB cascade response
[78][64]. The AGE–RAGE pathway promotes the intracellular activation of NADPH oxidase and the production of ROS. These pathological processes affect the majority of peripheral nerves
[37][23].
4.2. Macrovascular Complications and AGEs
Atherosclerotic CVDs, including ischemic heart disease, cerebrovascular disease, and atherosclerosis, are leading causes of death worldwide, including in Korea
[90,91][65][66]. Peripheral artery disease (PAD) with critical limb ischemia is also prevalent in type 2 DM. As previously mentioned, the etiology of DM complications is based on inflammation and changes in vasculature. Similar to the microvasculature, immune response and inflammation in vasculature are key factors in the pathogenesis of CVD. AGEs accumulation has been strongly related to cardiac pathophysiology. Recently, the role of AGEs in diabetic cardiomyopathy has been characterized by triggering the production of nitric oxide (NO) and inducing ventricular remodeling
[92,93][67][68]. AGEs act in the progression of CVD through the modification of extracellular and intracellular proteins and signaling cascades via AGE–RAGE pathways.